15. 封入体筋炎 Inclusion body myositis Clinical trials / Disease details
臨床試験数 : 42 / 薬物数 : 60 - (DrugBank : 16) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02483845 (ClinicalTrials.gov) | May 2013 | 31/5/2013 | Natalizumab in Inclusion Body Myositis (IBM) | Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis | Inclusion Body Myositis (IBM) | Drug: Natalizumab | Phoenix Neurological Associates, LTD | NULL | Active, not recruiting | 21 Years | 85 Years | All | 6 | Phase 1 | United States |